LOX-IN-3 dihydrochloride|cas:2409964-23-2|西域试剂

LOX-IN-3 dihydrochloride,99.97%

产品编号：Bellancom-138625A| CAS NO：2409964-23-2| 分子式：C₁₃H₁₅Cl₂FN₂O₂S| 分子量：353.24

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-138625A	￥3800.00	杭州北京（现货）
Bellancom-138625A	￥6000.00	杭州北京（现货）
Bellancom-138625A	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LOX-IN-3 dihydrochloride

产品介绍

LOX-IN-3 dihydrochloride 是一种具有口服活性的赖氨酰氧化酶 (lysyl oxidase (LOX)) 抑制剂，可用于纤维化，癌症和血管生成研究。

生物活性

LOX-IN-3 dihydrochloride is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 dihydrochloride can be used for fibrosis, cancer and angiogenesis research.

体外研究

LOX-IN-3 dihydrochloride monohydrate (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC₅₀ values of <10 μM and <1 μM, respectively.
LOX-IN-3 dihydrochloride monohydrate exhibits sustained inhibition of LOXL1 and LOXL2.
LOX-IN-3 dihydrochloride monohydrate is less active against SSAO/VAP-1 and MAO-B activities.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats.
LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model.
LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats
Dosage:	30 mg/kg
Administration:	Oral administration, single dose
Result:	Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC₅₀ after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).

Animal Model:	Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice
Dosage:	10 mg/kg
Administration:	Oral gavage, daily for 14 days
Result:	Increased kidney weight and thickness and reduced the area of fibrosis.

Animal Model:	C57Bl/6 mice, Bleomycin-induced lung fibrosis model
Dosage:	15 mg/kg
Administration:	Oral gavage, daily for 21 days
Result:	Significantly reduced the Ashcroft score and the lung weight.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats
Dosage:	30 mg/kg
Administration:	Oral administration, single dose
Result:	Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC₅₀ after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).

Animal Model:	Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice
Dosage:	10 mg/kg
Administration:	Oral gavage, daily for 14 days
Result:	Increased kidney weight and thickness and reduced the area of fibrosis.

Animal Model:	C57Bl/6 mice, Bleomycin-induced lung fibrosis model
Dosage:	15 mg/kg
Administration:	Oral gavage, daily for 21 days
Result:	Significantly reduced the Ashcroft score and the lung weight.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 100 mg/mL (283.09 mM)

DMSO : 33.33 mg/mL (94.36 mM; ultrasonic and warming and heat to 80°C)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8309 mL	14.1547 mL	28.3094 mL
5 mM	0.5662 mL	2.8309 mL	5.6619 mL
10 mM	0.2831 mL	1.4155 mL	2.8309 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.08 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.08 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明